Indivisible Partners Purchases New Stake in Gilead Sciences, Inc. $GILD

Indivisible Partners recently acquired a new stake of 9,379 shares in Gilead Sciences, Inc. valued at approximately $1.15 million during the fourth quarter. This move is part of broader institutional investment, with firms like Massachusetts Financial Services and Vanguard significantly increasing their holdings, bringing total institutional ownership to about 83.67%. Analysts have largely maintained a “Moderate Buy” rating for Gilead, with a consensus target price of $157.35, following the company’s Q4 2025 earnings beat and positive FY2026 guidance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin